| The effectiveness of yoga in modifying risk factors for cardiovascular disease and metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials P Chu, RA Gotink, GY Yeh, SJ Goldie, MGM Hunink European journal of preventive cardiology 23 (3), 291-307, 2016 | 300 | 2016 |
| Potential bias of instrumental variable analyses for observational comparative effectiveness research LF Garabedian, P Chu, S Toh, AM Zaslavsky, SB Soumerai Annals of internal medicine 161 (2), 131-138, 2014 | 148 | 2014 |
| Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids AK O'Sullivan, D Thompson, P Chu, DW Lee, EA Stewart, MC Weinstein International journal of technology assessment in health care 25 (1), 14-25, 2009 | 94 | 2009 |
| Comparative effectiveness of personalized lifestyle management strategies for cardiovascular disease risk reduction P Chu, A Pandya, JA Salomon, SJ Goldie, MGM Hunink Journal of the American Heart Association 5 (3), e002737, 2016 | 69 | 2016 |
| Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study DCA Taylor, A Pandya, D Thompson, P Chu, J Graff, J Shepherd, ... The European Journal of Health Economics 10, 255-265, 2009 | 49 | 2009 |
| Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada M Wagner, M Goetghebeur, E Merikle, A Pandya, P Chu, DCA Taylor Journal of Population Therapeutics and Clinical Pharmacology 16 (2), 2009 | 34 | 2009 |
| Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC) U Ondhia, HJ Conter, S Owen, A Zhou, J Nam, S Singh, A Abdulla, P Chu, ... Journal of medical economics 22 (7), 625-637, 2019 | 27 | 2019 |
| V, Benson, H., Fricchione, GL, & Hunink, MGM (2015). Standardised mindfulness-based interventions in healthcare: an overview of systematic reviews and meta-analyses of RCTs RA Gotink, P Chu, JJ Busschbach PloS One 10 (4), e0124344, 0 | 21 | |
| Budgetary impact of varenicline in smoking cessation in the United Kingdom DCA Taylor, P Chu, VM Rosen, CL Baker, D Thompson Value in Health 12 (1), 28-33, 2009 | 14 | 2009 |
| Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy P Chu, S Batson, M Hodgson, CR Mitchell, A Steenrod Future Oncology 16 (4), 61-74, 2020 | 13 | 2020 |
| Comparative efficacy of second-and subsequent-line treatments for metastatic NSCLC: a fractional polynomials network meta-analysis of cancer immunotherapies C Schulz, D Gandara, CG Berardo, R Rosenthal, J Foo, C Morel, ... Clinical Lung Cancer 20 (6), 451-460. e5, 2019 | 13 | 2019 |
| Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer P Chu, M Antoniou, MK Bhutani, A Aziez, M Daigl Journal of Comparative Effectiveness Research 9 (15), 861-876, 2020 | 9 | 2020 |
| Identifying high-value lifestyle interventions for cardiovascular disease prevention PN Chu | 1 | 2016 |
| PIH7 COST-EFFECTIVENESS OF MAGNETIC RESONANCE IMAGE-GUIDED FOCUSED ULTRASOUND (MRGFUS) FOR THE TREATMENT OF UTERINE FIBROIDS AK O'Sullivan, MC Weinstein, D Thompson, P Chu, DW Lee, EA Stewart Value in Health 10 (6), A374-A375, 2007 | 1 | 2007 |
| Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in spain and germany DCA Taylor, A Pandya, D Thompson, P Chu, J Graff, JC LaRosa, ... Atherosclerosis supplements 8 (1), 125-125, 2007 | 1 | 2007 |
| Mo-P5: 344 Cost-effectiveness of intensive lipid-lowering treatment with atorvastatin 80MG versus 10MG in secondary cardiovascular prevention in the UK DCA Taylor, A Pandya, D Thompson, P Chu, J Graff, M Drummond, ... Atherosclerosis (Supplements)(Component) 3 (7), 121, 2006 | 1 | 2006 |
| Matching-adjusted indirect comparison (MAIC) of entrectinib▼ versus crizotinib in patients with ROS1 non-small cell lung cancer (NSCLC): an updated analysis P Chu, C Mitchell, S Batson lung cancer 36, 1405-1411, 2020 | | 2020 |
| PCN18 Matching-Adjusted Indirect Comparison (MAIC) of Entrectinib Versus Crizotinib in Patients with ROS1 NON-SMALL CELL LUNG Cancer (NSCLC): An Updated Analysis P Chu, CR Mitchell, S Batson, A Aziez, M Antoniou Value in Health 23, S423-S424, 2020 | | 2020 |
| Abstract C090: Systematic review of neurotrophic tyrosine receptor kinase inhibition as a tumor-agnostic management strategy P Chu, S Batson, C Mitchell, M Hodgson Molecular Cancer Therapeutics 18 (12_Supplement), C090-C090, 2019 | | 2019 |
| MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS P Chu, M Antoniou, MK Bhutani, A Aziez, M Daigl ISPOR Europe 2019, 2019 | | 2019 |
